Summary In a single centre, 52 newly diagnosed patients with acute myeloid leukaemia (AML) under the age of 56 years received induction chemotherapy commencing with high-dose cytosine arabinoside (Ara-C) and etoposide (Protocol BFI 1), followed by Ara-C, 6 thioguanine (6TG). A total of 67% of patients entered remission using these drugs. An anthracycline was added for those patients not in remission. The overall remission rate (CR) was 86.5% (45/52), with a minimum follow-up of 90 days. Patients are hospitalised for relatively short periods, and consequently require less blood product and antibiotic support. Patients in continuing first remission following, induction with Ara-C and etoposide are similar in number to those in continuing first remission who initially received an anthracycline. This would imply that the efficiency of Ara-C and etoposide in inducing long-term disease-free survival is comparable with anthracycline-containing regimens. We conclude that high-dose Ara-C and etoposide used in the first induction cycle for treating AML have good antileukaemic effect with acceptable toxicity.Patients with AML with first remission can now expect a cure rate of 45-60% following either ABMT or BMT (Hurd, 1987). These results, however, depend upon obtaining remission, higher CR rates rendering more

Background: Equine glandular gastric disease (EGGD) is an erosive disease of the glandular mucosa of the stomach, which is increasingly recognised as a potential cause of poor performance, girthing pain and behavioural changes in sport horses. Unfortunately, the cause of EGGD has not yet been identified, and thus targeted treatment is not possible. Therefore, current recommendations for treatment and prevention are based on acid suppression and management strategies aimed at mitigating known risk factors.Aim of the article: This article summarises what we currently know about EGGD and outlines how we can use this information to manage the disease more effectively.